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ABSTRACT
Objective: To compare unsatisfactory rates between
the two major liquid-based cytology (LBC) platforms,
namely ThinPrep (Hologic) and SurePath (Becton
Dickinson).
Design: The authors performed both a systematic
review and a meta-analysis. Inclusion criteria were
English language, data presented on unsatisfactory
rates for either ThinPrep or SurePath, utilising actual
patient samples (ie, not laboratory manipulated
samples) and no manipulation using acetic acid to
increase the satisfactory rate. The authors searched
PubMed for articles using the keywords ‘SurePath’ or
‘ThinPrep’ and ‘unsatisfactory’. References of retrieved
studies were searched for additional articles. Key
researchers in the ﬁeld were also contacted.
Participants and interventions: Eligible studies
were reviewed for rates of unsatisfactory cervical
cytology smears processed on either the ThinPrep or
SurePath platforms (compared with a general linear
model) or data on unsatisfactory rates for both
platforms for the same laboratory and the same patient
population (compared with a meta-analysis using
a random effects model and pooled RR).
Primary Outcome Measure: Unsatisfactory rate of
cervical cytology smears.
Results: A total of 1120418 cervical cytology smears
were reported in 14 different studies using the SurePath
platform for an overall unsatisfactory rate (weighted
average) of 0.3%. 28 studies reported on 1148755
smears prepared using the ThinPrep platform for an
overall unsatisfactory rate (weighted average) of 1.3%.
The general linear model did not show a difference
between LBC platforms when other variables were
controlled for; however, the power to detect a difference
(0.087) was very low. The meta-analysis performed on
four studies where both ThinPrep and SurePath results
were reported from the same laboratory showed fewer
unsatisfactory tests from the SurePath platform (RR
0.44, 95% CI 0.25 to 0.77, p¼0.004).
Conclusions: Multiple factors affect LBC
unsatisfactory rates. In a meta-analysis, cervical
cytology samples prepared on the SurePath platform
show signiﬁcantly fewer unsatisfactory smears than
those prepared on the ThinPrep platform.
INTRODUCTION
Since ﬁrst introduced in the late 1990s,
liquid-based cytology (LBC) was quickly
adopted by many laboratories as a great
improvement in the performance of gynae-
cologic cytology. The method permits labo-
ratories to create slides rather than having
prepared slides sent to them in various
degrees of ﬁxation and preparation. The
LBC methodology also provides a cleaner
smear as the proprietary methods remove
obscuring elements such as blood and
inﬂammation. This ‘cleaning’ of samples is
often cited as the reason there are lower
unsatisfactory rates in LBC.
1 The liquid
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ARTICLE SUMMARY
Article focus
- Two major LBC platforms are commonly used
(ThinPrep (Hologic) and SurePath (Becton Dick-
inson))
- These employ different sample preparation
methodologies, which may result in different
unsatisfactory rates.
Key messages
- Multiple factors are associated with LBC unsat-
isfactory rates.
- Cervical cytology samples prepared on the
SurePath platform show signiﬁcantly fewer
unsatisfactory smears than those prepared on
the ThinPrep platform.
- Unsatisfactory samples represent a missed
opportunity for screening
Strengths and limitations of this study
- Large sample size from multiple studies
- Relatively few studies performed a head-to-head
evaluation of the two platforms
- Restriction to English literature and use of only
one bibliographic search base (Medline) are
limitations.
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Open Access Researchplatforms also allow for reﬂex testing for human papil-
loma virus for borderline cases. However, large trials and
a meta-analysis have recently shown that the perfor-
mance of LBC may be equivalent to conventional
cytology, thus making it difﬁcult for laboratories to justify
the added expense of LBC.
2e4
When considering LBC, laboratories are faced with
a decision between two main platforms produced by
ThinPrep (Hologic) and SurePath (Becton Dickinson).
Both technologies are Food and Drug Administration
approved but employ different methodologies in sample
preparation. In light of these differences in preparation,
we set out to evaluate the existing English literature
comparing the performance of each platform with
respect to unsatisfactory rates.
METHODS
Information sources and search strategy
Our meta-analysis adhered to the PRISMA statement for
reporting on meta-analyses.
5 The initial literature search
for articles was conducted using PubMed. Articles
published in English between 1 January 1990 and 1
August 2011 were retrieved using the search words
‘unsatisfactory’ and ‘ThinPrep or SurePath’. These date
range were chosen to coincide with the period following
the introduction of The Bethesda System (TBS) in
1989.
6 The references of the retrieved papers were
examined for further possible studies not detected in
the initial literature search. Additionally, we searched
major clinical trial registries (http://clinicaltrials.gov,
http://isrctn.org, http://www.umin.ac.jp/ctr/index/
htm/, http://www.anzctr.org.au/Default.aspx, http://
www.trialregister.nl/trialreg/index.asp, http://apps.
who.int/trialsearch) using the search words ‘liquid-
based cytology’, contacted both manufacturers and
contacted key researchers in the ﬁeld to check for
ongoing or unpublished studies.
Study selection and eligibility criteria
Eligible studies for the review presented rates of tech-
nically unsatisfactory cervical cytology smears performed
on either ThinPrep or SurePath platform. For inclusion
in the meta-analysis, studies must have presented data on
unsatisfactory cervical cytology smears performed on
both ThinPrep and SurePath platforms by the same
laboratory on the same patient population. Only studies
presented in English were considered. Both published
and unpublished studies were considered to be eligible
for inclusion.
The initial search retrieved 76 papers. The abstracts of
these papers were reviewed by CN and DF and 46 were
chosen for full review. An additional six published
studies were subsequently identiﬁed as well as one
unpublished study. Of these articles, 42 met the further
inclusion criteria of presenting data on unsatisfactory
rates for either ThinPrep or SurePath and utilising
actual patient samples (ie, not laboratory manipulated
samples) and not employing glacial acetic acid to
increase the satisfactory rate. Four of these studies
presented data on both ThinPrep and SurePath use in
the same population by the same laboratory and were
therefore included in the meta-analysis. Our contacts
with industry and other researchers did not reveal
additional usable studies. The selection process is
summarised in ﬁgure 1.
Data extraction
Two of the authors (CN and DF) extracted data inde-
pendently from the 42 studies meeting the inclusion
criteria. These results were then compared and any
discrepancies resolved. The following data were
extracted: (1) number of patients included, (2) type of
liquid-based system used (ThinPrep or SurePath), (3)
per cent of unsatisfactory cases, (4) country of study, (5)
year of study, (6) whether image analysis software was
used to screen the slides and (7) the number of women
in the study (sample size). The lack of ambiguity of the
outcome measure (only two end points are possible:
unsatisfactory or satisfactory), combined with the irrele-
vance of a follow-up (latent) period, obviated the need
for quality scoring of the included studies.
Statistical analysis
Unsatisfactory rates were ﬁrst compared using a univar-
iate general linear model in SPSS V.19. The dependent
variable was unsatisfactory rate, and the dependent
variables were year of study (divided into 2002 and
before to capture studies published before TBS revision
in 2001 and 2003 and later), platform (ThinPrep vs
SurePath), country where study was performed and
whether image analysis software was used. Studies were
weighted by the number of women participating in
each one. In addition to the signiﬁcance level, observed
power was calculated for each variable. Differences
were considered signiﬁcant at an a level of 0.05. Meta-
analysis was then performed using Review Manager
V.4.2.
7 A c
2 test for heterogeneity among studies
included in the meta-analysis revealed an I
2 of 97% with
apv a l u eo f<0.00001, indicating signiﬁcant
Records iden ﬁed  Addi onal records Unpublished
through Medline
search (n=76)
iden ﬁed through
other sources (n=6)
studies
solicited (n=1)
Records screened:
abstracts (n=83)
Records excluded:
not cervical cytology
(n=20)
Did
Full-text ar cles
not use ThinPrep or
SurePath (n=2)
Not wri en in English
(n=2)
excluded: did not
present results in
truth table (n=16)
Duplicated data (n=1)
Records included in quan ta ve synthesis (n=42)
Records included in meta-analysis (n=4)
Figure 1 Selection of studies of unsatisfactory rates of
cervical cytology smears prepared with ThinPrep and
SurePath platforms.
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Liquid-based cytology unsatisfactory ratesheterogeneity among these studies (although the
heterogeneity was quantitative rather than qualitative as
all the trials demonstrated the same trend). Therefore,
a random effects model was employed to calculate the
pooled OR.
RESULTS
A total of 1120418 cervical cytology smears were
reported in 14 different studies using the SurePath
platform (table 1). The pooled unsatisfactory rate
(weighted average) was 0.3%. For cervical cytology
smears processed on the ThinPrep platform, 28 studies
reported on 1148755 smears for a pooled unsatisfactory
rate (weighted average) of 1.3% (table 2). A general
linear model as previously described was employed to
test for a difference in unsatisfactory rate ThinPrep and
SurePath. Year of publication (p¼0.021) and country
where research was performed (p¼0.004) were inde-
pendent predictors of unsatisfactory rate. The use of
image analysis software (p¼0.091) and the LBP plat-
form used (p¼0.558) were not independent predictors
of unsatisfactory rate. However, the observed power for
LBP platform was very low at 0.087, making the risk of
a type II error high. To attempt to gain statistical power,
we performed a meta-analysis where we considered only
studies where both platforms were evaluated on the
same patient population by the same laboratory. We
found three such studies in the published literature and
added data from one additional unpublished study
(table 3). All four of these studies reported similar
populations but different patients who were screened
with either ThinPrep or SurePath platform. The pooled
RR from the meta-analysis was 0.44 (95% CI 0.25 to
0.77) in favour of SurePath over ThinPrep (ﬁgure 2). A
Z-test for overall effect was statistically signiﬁcant at
p¼0.004.
Because of the small number of studies included in the
meta-analysis, a funnel plot was not informative.
However, the four included showed similar unsatisfac-
tory rates to other studies and therefore we felt were
representative of the other studies retrieved.
DISCUSSION
Despite being one of the most successful screening tests
for cancer, cervical cytology smears have been criticised
for low sensitivity. False-negative cervical cytology smears
are responsible for this decrease in sensitivity and may
result from collection errors, screening errors or inter-
pretation errors.
We set out to examine unsatisfactory rates in LBC as
these have been demonstrated to be largely reproducible
within laboratories but not across laboratories.
43 Most
laboratories use TBS or some modiﬁcation thereof for
interpretation of cervical cytology smears. We could not,
however, establish the criteria used to determine
adequacy for each platform; some laboratories use the
methods described in the manufacturer’s guide (TBS
based), while others have adopted their own criteria and
many authors do not elaborate on this in their methods.
Furthermore, our results showed that year of publication
and to a greater extent country were signiﬁcant
confounding factors in the comparison of unsatisfactory
rates between ThinPrep and SurePath platforms. These
confounding factors resulted in very low power to detect
a statistically signiﬁcant difference in unsatisfactory rates,
despite a wide difference in mean unsatisfactory rates
Table 1 Unsatisfactory cervical cytology smear rates in populations using the SurePath platform
Lead author Year
Total number of
cervical cytology
smears
Number of
unsatisfactory
smears
Percentage of
unsatisfactory
smears
Location
of study
Colgan et al
8 2004 352680 915 0.3 Canada
Zhao et al
9 2011 972 2 0.2 China
Kirscher et al
10 2006 84414 292 0.3 Denmark
Beerman et al
11 2008 35315 46 0.1 the Netherlands
Sykes et al
12 2008 451 12 2.7 New Zealand
Sykes et al
12 2008 457 12 2.6 New Zealand
Kitchener et al
13 2011 22145 354 1.6 UK
Narine and
Young
14
2007 53982 208 0.4 UK
Narine and
Young
14
Unpublished 27738 327 1.2 UK
Alsharif et al
15 2009 232022 360 0.2 USA
Stark
16 2007 137703 302 0.2 USA
Nance
17 2007 92875 158 0.2 USA
Fremont-Smith
et al
18
2004 58580 130 0.2 USA
Sass
19 2003 8771 14 0.2 USA
Wilbur et al
20 2009 12313 27 0.2 USA
Total 1120418 3159 0.3
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Liquid-based cytology unsatisfactory ratesTable 3 Studies included in the meta-analysis
Lead author Year Platform
Total number
of cervical
cytology smears
Number of
unsatisfactory
smears
Percentage of
unsatisfactory
smears
Location
of study
Zhao et al
9 2011 TP 972 2 1.5 China
Zhao et al
9 2011 SP 1033 15 0.2 China
Kitchener et al
13 2011 TP 23436 456 2.0 UK
Kitchener et al
13 2011 SP 22145 354 1.6 UK
Narine and
Young
14
Unpublished TP 58973 1250 2.1 UK
Narine and
Young
14
Unpublished SP 27738 327 1.2 UK
Nance
17 2007 TP 88575 567 0.6 USA
Nance
17 2007 SP 92875 158 0.2 USA
SP, SurePath; TP, ThinPrep.
Table 2 Unsatisfactory cervical cytology smear rates in populations using the ThinPrep platform
Lead author Year
Total number
of cervical
cytology smears
Number of
unsatisfactory
smears
Percentage of
unsatisfactory
smears Location of study
Davey et al
21 2007 52665 795 1.5 Australia
Roberts et al
22 1997 35560 235 0.7 Australia
Shield et al
23 1999 300 19 6.3 Australia
Halford et al
24 2009 87284 758 0.9 Australia
Duggan et al
25 2006 2288 10 0.4 Canada
Belison et al
26 2002 1450 158 10.9 China
Zhao et al
9 2011 1033 15 1.5 China
Yeoh et al
27 1999 16541 93 0.6 Hong Kong
Cheung et al
28 2003 190667 608 0.3 Hong Kong
Grace et al
29 2002 1000 13 1.3 Ireland
Treacy et al
1 2009 41312 1342 3.2 Ireland
Ronco et al
30 2007 22708 583 2.6 Italy
Rahimi et al
31 2008 467 9 1.9 Italy
Luthra et al
32 2001 1024 36 3.5 Kuwait
Siebers et al
33 2008 46064 153 0.3 the Netherlands
Williams
34 2006 78064 1493 1.9 Scotland
Taylor et al
35 2006 3184 70 2.2 South Africa
Tuncer et al
36 2005 4322 72 1.7 Turkey
Kitchener et al
13 2011 23436 456 1.9 UK
Narine and
Young
14
Unpublished 58973 1250 2.1 UK
Alsharif et al
15 2009 5419 124 2.3 USA
Nance
17 2007 88575 567 0.6 USA
Bentz
37 2002 23790 209 0.9 USA
Bentz
37 2002 15154 197 1.3 USA
Bolick and
Hellman
38
1998 10694 31 0.3 USA
Wachtel et al
39 2009 2890 77 2.7 USA
Harkness et al
40 2003 3000 80 2.7 USA
Duby and
DiFurio
41
2009 55438 1027 1.8 USA
Duby and
DiFurio
41
2009 53209 783 1.5 USA
Zhao and
Austin
42
2009 222242 3230 1.4 USA
Total 1148755 15593 1.3
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Liquid-based cytology unsatisfactory ratesbetween the two platforms. In contrast, a meta-analysis
comparing four head-to-head studies did reveal a lower
unsatisfactory rate for the SurePath platform. These
differences underscore the fact that multiple factors are
associated with overall unsatisfactory rates with the plat-
form used representing only one of these.
It is also acknowledged that there are other possible
biases in the source literature that our analyses could not
control for. These include the relative experience of the
cytologists in reading slides prepared using one or the
other platform and any possible undisclosed biases in
the allocation of individuals to treatment groups in the
four head-to-head studies. The differences in unsatis-
factory rates due to LBC platform we report here are
most likely a function of differences in the proprietary
methodology for each platform. ThinPrep employs
a ﬁlter-based technology, while SurePath uses a density/
sedimentation process. Differences are also encountered
when collecting the sample; ThinPrep requires the
collector to rinse the collection device in the liquid
media that is followed by disposal of the collection
device. In contrast, the SurePath collection device is
placed in the media and sent to the laboratory for
processing. This difference has been demonstrated to
account for up to 38% loss of the ThinPrep sample in
a study by Bigras et al.
44 These preparatory differences
represent a signiﬁcant technical difference, which labo-
ratories must consider prior to adopting LBC. However,
counterbalancing this loss of sample is the fact that
ThinPrep samples are signiﬁcantly less labour intensive
than SurePath samples for the processing laboratory.
As tables 1 and 2 show, there was considerable varia-
tion in unsatisfactory rates among jurisdictions, with
countries in the European Union in particular tending
to show higher unsatisfactory rates in both studies of
SurePath and ThinPrep. This is likely attributable to
variations in adequacy criteria compared with TBS.
Both the SurePath (FocalPoint GS) and ThinPrep
(ThinPrep Imager) systems include optional computer-
assisted digital image analysis software. If we examine
only studies using this technology, three studies using
the ThinPrep Imager all gave unsatisfactory rates of
1.5%
21 41 42dsimilar to other ThinPrep studies included
in this review. The single study evaluating the FocalPoint
GS system showed an unsatisfactory rate of 0.2%,
19 again
similar to the other SurePath studies reviewed.
Reprocessing of unsatisfactory ThinPrep slides using
glacial acetic acid can decrease the unsatisfactory rates
by 30%e40%.
45 However, use of this technique still
would not result in equivalency with SurePath unsatis-
factory rates and introduces additional issues including
a higher false-positive rate
46 and interferes with the
ability to perform hybrid capture human papilloma virus
testing.
47
The data presented here show a signiﬁcant difference
between the different platforms with SurePath having
a signiﬁcantly lower rate of unsatisfactory samples. This
pattern was observed when considering different coun-
tries and methods used to determine thresholds for
unsatisfactory designation. Consistent with this observa-
tion are data from a College of American Pathologist
survey reporting differences in unsatisfactory rates
between laboratories using SurePath (median unsatis-
factory rate 0.3%) and ThinPrep (median unsatisfactory
rate 1.1%) platforms.
48 These numbers are similar to the
pooled unsatisfactory rates we report in this study (0.3%
for SurePath and 1.3% for ThinPrep).
A limitation of our study is that it considers only one
aspect of LBP platform selection (unsatisfactory rate),
whereas other factors such as speciﬁcity and sensitivity
must also be considered. A discussion of this is outside
the scope of this paper but interested readers are
referred to the meta-analysis of Arbyn et al
4 for further
information. The implication of this unsatisfactory rate
difference is also a consideration for specimens, which
could be biobanked for further studies to evaluate new
biomarkers and how they may perform in unsatisfactory
LBC samples.
49
Unsatisfactory samples represent a missed opportunity
for screening
50 and are more often associated with
a cervical abnormality.
51 It has also been well described
that patients with an invasive cervical cancer have
a much greater rate of unsatisfactory Pap smears, often
as a result of scant cellularity and obscuring elements
such as blood and inﬂammation.
52e54 In addition to the
technical requirements of sample preparation, labora-
tories may wish to consider the variation in unsatisfactory
sample rates when choosing an LBC platform.
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Figure 2 Meta-analysis of the
association between rate of
unsatisfactory cervical smears and
processing platform (ThinPrep and
SurePath).
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